Patents by Inventor Paul Steverink

Paul Steverink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aberrant cell-restricted immunoglobulins provided with a toxic moiety
    Patent number: 10946104
    Abstract: Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes. The provided immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: March 16, 2021
    Assignee: APO-TB.V.
    Inventors: Johan Renes, Paul Steverink, Ralph Alexander Willemsen
  • BINDING MOLECULES TARGETING PATHOGENS
    Publication number: 20150175683
    Abstract: A first aspect of the disclosure relates to the field of binding molecules targeted at pathogens. The disclosure further relates to proteinaceous binding molecules targeting cells displaying pathogen-associated molecular patterns, in particular targeting cell surface molecules associated with or derived from pathogens, more in particular cell surface proteins displaying peptides from intracellular (pathogen associated) proteins.
    Type: Application
    Filed: June 26, 2013
    Publication date: June 25, 2015
    Applicant: APO-T B.V.
    Inventors: Johan Renes, Paul Steverink, Ralph Alexander Willemsen
  • ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY
    Publication number: 20150056198
    Abstract: Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes. The provided immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.
    Type: Application
    Filed: January 11, 2013
    Publication date: February 26, 2015
    Inventors: Johan Renes, Paul Steverink, Ralph Alexander Willemsen